Holen Sie sich die Stockscreener-App
16.99
1.07%
0.18
Handel nachbörslich:
16.99
Schlusskurs vom Vortag:
$16.81
Offen:
$16.82
24-Stunden-Volumen:
672.56K
Relative Volume:
1.24
Marktkapitalisierung:
$1.03B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-5.7399
EPS:
-2.96
Netto-Cashflow:
$-154.68M
1W Leistung:
+1.61%
1M Leistung:
+5.14%
6M Leistung:
-6.75%
1J Leistung:
-39.32%
1-Tages-Spanne:
$16.23
$17.33
1-Wochen-Bereich:
$16.12
$17.44
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
16.99 | 1.00B | 688.00K | -170.19M | -154.68M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
What’s the RSI of Spyre Therapeutics Inc. stock2025 Growth vs Value & AI Powered Market Entry Ideas - khodrobank.com
What is Spyre Therapeutics Inc.’s valuation compared to sectorBull Run & Daily Profit Focused Screening - khodrobank.com
Should you hold or exit Spyre Therapeutics Inc. now2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
Custom watchlist performance reports with Spyre Therapeutics Inc.Portfolio Update Summary & Stepwise Swing Trade Plans - Newser
Can Spyre Therapeutics Inc. hit a new high this monthJuly 2025 EndofMonth & Reliable Price Breakout Alerts - Newser
What technical models suggest about Spyre Therapeutics Inc.’s comebackWeekly Profit Recap & Verified Trade Idea Suggestions - Newser
Visualizing Spyre Therapeutics Inc. stock with heatmapsTake Profit & Risk Adjusted Buy/Sell Alerts - Newser
Combining machine learning predictions for Spyre Therapeutics Inc.Market Weekly Review & Low Risk Growth Stock Ideas - Newser
Combining price and volume data for Spyre Therapeutics Inc.July 2025 Final Week & Verified Technical Signals - Newser
Chart based exit strategy for Spyre Therapeutics Inc.Earnings Growth Report & Technical Pattern Recognition Alerts - Newser
What are the future prospects of Spyre Therapeutics Inc.IPO Watch & Proven Capital Preservation Methods - khodrobank.com
Spyre Therapeutics Inc. stock trend forecastEarnings Growth Report & Smart Investment Allocation Insights - Newser
How to build a custom watchlist for Spyre Therapeutics Inc.Wall Street Watch & Fast Gaining Stock Strategy Reports - Newser
Is Spyre Therapeutics Inc. stock a buy or sell2025 Dividend Review & Low Risk High Win Rate Picks - khodrobank.com
Does Spyre Therapeutics Inc. stock benefit from AI growthJuly 2025 PostEarnings & AI Enhanced Trading Alerts - khodrobank.com
Does Spyre Therapeutics Inc. align with a passive investing strategyJuly 2025 PreEarnings & Low Risk High Win Rate Picks - khodrobank.com
Is Spyre Therapeutics Inc. trending in predictive chart models2025 Price Action Summary & Safe Swing Trade Setup Alerts - Newser
Is Spyre Therapeutics Inc. benefiting from interest rate changesJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - khodrobank.com
Can Spyre Therapeutics Inc. disrupt its industry2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - khodrobank.com
Can Spyre Therapeutics Inc. withstand a market correctionMarket Rally & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Published on: 2025-09-01 18:05:22 - khodrobank.com
Will Spyre Therapeutics Inc. bounce back from current supportWeekly Trade Review & Verified Short-Term Plans - Newser
Real time scanner hits for Spyre Therapeutics Inc. explainedMarket Movement Recap & Entry Point Confirmation Signals - Newser
Relative strength of Spyre Therapeutics Inc. in sector analysisWeekly Trade Analysis & Reliable Intraday Trade Alerts - Newser
Spyre Therapeutics Inc.’s volatility index tracking explainedGDP Growth & Safe Capital Growth Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Will a bounce in Spyre Therapeutics Inc. offer an exitDividend Hike & Smart Money Movement Alerts - Newser
What high frequency data says about Spyre Therapeutics Inc.July 2025 Volume & Capital Efficient Trading Techniques - Newser
Nuveen LLC Makes New Investment in Spyre Therapeutics, Inc. $SYRE - Defense World
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMarket Risk Analysis & Stock Portfolio Risk Management - Newser
Can Spyre Therapeutics Inc. recover in the next quarterDip Buying & Safe Swing Trade Setups - Newser
Spyre Therapeutics Inc. stock trend outlook and recovery path2025 Short Interest & Free Growth Oriented Trading Recommendations - Newser
Spyre Therapeutics Inc. Consolidation Zone May Signal AccumulationJuly 2025 Intraday Action & Fast Moving Stock Trade Plans - sundaytimes.kr
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Nov 06 '24 |
Sale |
36.76 |
6,700 |
246,313 |
27,360 |
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):